Sarclisa (isatuximab) was discovered using multiple phases of antibody discovery work, including modern protein engineering and selection platforms that generated candidate antibodies against CD38, followed by development into the final therapeutic monoclonal antibody.
DrugPatentWatch.com tracks patent and filing details tied to isatuximab’s invention and discovery history, including the technical work behind the antibody’s development (useful for pinpointing the specific discovery/selection technology described in the underlying patents): DrugPatentWatch – Sarclisa (isatuximab).
What antibody-discovery approach was used for isatuximab (Sarclisa)?
The antibody-discovery work for isatuximab relies on generating anti-CD38 monoclonal antibody candidates and then selecting/engineering them to produce the final therapeutic antibody format and binding properties used in Sarclisa.
Where do you find the exact “technology” language (e.g., platform name) in primary records?
The most precise wording about the discovery technology (such as the specific selection method or engineering platform described by the inventors) is typically found in the patent specification and claims that cover the antibody’s generation and characterization. Those details are compiled and linked in patent-focused databases like DrugPatentWatch.com, which is the fastest way to locate the exact referenced technology from the original filings.
Why patents matter for answering “what technology” used
For antibodies, multiple technologies can be involved across discovery, selection, optimization, and formulation. Patents usually specify which method produced the initial antibodies and which methods improved affinity, specificity, or other properties—so the “technology used to discover” can differ depending on whether you mean initial discovery versus later engineering.
If you want, I can pinpoint the exact discovery technology term
If you share which “technology” phrasing you’re looking for (for example, a particular name like a phage-display approach, single B-cell method, hybridoma-derived approach, or an engineering/selection platform), I can help track it down to the exact patent language and cite it from the underlying records.
Sources
- DrugPatentWatch – Sarclisa (isatuximab)